Inclusion in TOPIX was decided, with incorporation starting on 2026-10-30. With a view to expanding exposure to institutional investors and stabilizing the shareholder base, the company aims to enhance long-term value based on its global expansion and growth strategy in the pharmaceutical business.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Group Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-07","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/2160-20261007-01.pdf","jir_short_summary":"Inclusion in TOPIX was decided, with incorporation starting on 2026-10-30. With a view to expanding exposure to institutional investors and stabilizing the shareholder base, the company aims to enhance long-term value based on its global expansion and growth strategy in the pharmaceutical business.","jir_summary":"### Overview of TOPIX Inclusion and Market Segment Reform\nThis IR announces that GNI Group has been selected as a TOPIX constituent, marking the first occasion for the company to move from the Growth Market to being included in TOPIX. The inclusion will take effect on 2026-10-30, and in the second phase of the TOPIX reform, regular rebalancing will be introduced across all market segments including Growth, Prime, and Standard.\n\n### Corporate Growth Strategy and Investor Opportunities\nThe company completed the acquisition of Ayumi Pharmaceutical's Calonal in July 2026 and is advancing a strong sales base centered on Japan alongside global expansion. TOPIX inclusion is expected to broaden investment opportunities for institutional investors such as ETFs and index funds, and to improve recognition and stabilize the shareholder base domestically and internationally.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#GNIGroup, #TOPIXInclusion, #MarketSegmentReform","jir_key_figures":"TOPIX constituent inclusion date: 2026-10-30\nAcquisition completion date: July 2026 (as stated in the text)\nGlobal presence: Japan \u00b7 China \u00b7 USA \u00b7 Australia","jir_meta_title":"GNI Group Ltd. \u2014 TOPIX Inclusion Expands Institutional Investor Opportunities | October 2026","jir_meta_description":"GNI Group Ltd. has been selected as a TOPIX constituent in the first regular rebalancing following market reforms. Backed by a completed acquisition and global expansion, the company targets medium- to long-term value enhancement.","jir_og_title":"TOPIX Inclusion to Expand Institutional Investor Base \u2014 GNI Group Ltd.","jir_og_description":"Selected in the first regular rebalancing after TOPIX reform. Explains growth strategy leveraging expanded domestic and international investor opportunities and increased recognition.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-128232","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n